Trial Profile
A Phase I clinical trial of an undisclosed antibody candidate
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2018
Price :
$35
*
At a glance
- Drugs Antibody therapeutic Agenus/Merck AG (Primary)
- Indications Cancer
- Focus Adverse reactions
- 31 Aug 2018 New trial record
- 15 Aug 2018 According to an Agenus media release, Agenus received a $4 million milestone payment and is entitled to receive up to an additional $95 million in success milestones from Merck.